Phocas Financial Corp. lifted its stake in shares of Diplomat Pharmacy Inc (NYSE:DPLO) by 142.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 663,187 shares of the company’s stock after buying an additional 390,168 shares during the quarter. Diplomat Pharmacy comprises about 1.1% of Phocas Financial Corp.’s holdings, making the stock its 23rd biggest holding. Phocas Financial Corp. owned 0.96% of Diplomat Pharmacy worth $13,310,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors also recently modified their holdings of the company. The Manufacturers Life Insurance Company raised its position in Diplomat Pharmacy by 3.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 37,644 shares of the company’s stock valued at $557,000 after purchasing an additional 1,211 shares during the last quarter. Wrapmanager Inc. raised its position in Diplomat Pharmacy by 14.4% in the 4th quarter. Wrapmanager Inc. now owns 16,212 shares of the company’s stock valued at $325,000 after purchasing an additional 2,044 shares during the last quarter. Teachers Advisors LLC raised its position in Diplomat Pharmacy by 0.9% in the 4th quarter. Teachers Advisors LLC now owns 297,999 shares of the company’s stock valued at $5,981,000 after purchasing an additional 2,541 shares during the last quarter. American International Group Inc. raised its position in Diplomat Pharmacy by 7.3% in the 3rd quarter. American International Group Inc. now owns 37,836 shares of the company’s stock valued at $784,000 after purchasing an additional 2,587 shares during the last quarter. Finally, Invictus RG raised its position in Diplomat Pharmacy by 24.4% in the 3rd quarter. Invictus RG now owns 13,820 shares of the company’s stock valued at $286,000 after purchasing an additional 2,707 shares during the last quarter. Institutional investors and hedge funds own 64.64% of the company’s stock.
Diplomat Pharmacy Inc (NYSE:DPLO) opened at $23.20 on Tuesday. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.97 and a quick ratio of 0.66. The stock has a market cap of $1,685.07, a price-to-earnings ratio of 110.48 and a beta of 1.32. Diplomat Pharmacy Inc has a 12 month low of $14.00 and a 12 month high of $27.78.
Diplomat Pharmacy (NYSE:DPLO) last announced its quarterly earnings data on Monday, February 26th. The company reported $0.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.16 by $0.02. The company had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.17 billion. Diplomat Pharmacy had a net margin of 0.35% and a return on equity of 8.89%. Diplomat Pharmacy’s revenue was up .9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.08 EPS. equities research analysts anticipate that Diplomat Pharmacy Inc will post 0.94 earnings per share for the current fiscal year.
Several analysts recently commented on the stock. Wells Fargo reiterated a “market perform” rating and issued a $25.00 price target (up previously from $21.50) on shares of Diplomat Pharmacy in a research report on Tuesday, February 27th. Needham & Company LLC set a $28.00 price target on shares of Diplomat Pharmacy and gave the company a “buy” rating in a research report on Tuesday, February 27th. Zacks Investment Research downgraded shares of Diplomat Pharmacy from a “buy” rating to a “hold” rating in a research report on Wednesday, February 21st. Deutsche Bank upgraded shares of Diplomat Pharmacy from a “hold” rating to a “buy” rating in a research report on Friday, March 2nd. Finally, Leerink Swann set a $30.00 price target on shares of Diplomat Pharmacy and gave the company a “buy” rating in a research report on Tuesday, February 27th. Eight equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Diplomat Pharmacy presently has a consensus rating of “Hold” and a consensus target price of $25.38.
In other Diplomat Pharmacy news, Director Philip R. Hagerman sold 2,150,000 shares of the business’s stock in a transaction on Friday, March 9th. The shares were sold at an average price of $20.65, for a total value of $44,397,500.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 30.20% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://ledgergazette.com/2018/03/20/diplomat-pharmacy-inc-dplo-stake-increased-by-phocas-financial-corp.html.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Want to see what other hedge funds are holding DPLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Diplomat Pharmacy Inc (NYSE:DPLO).
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.